People s United Financial Inc. Acquires 2,653 Shares of AstraZeneca PLC (NASDAQ:AZN)

People s United Financial Inc. grew its position in AstraZeneca PLC (NASDAQ:AZN) by 10.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,304 shares of the company’s stock after purchasing an additional 2,653 shares during the period. People s United Financial Inc.’s holdings in AstraZeneca were worth $1,636,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Tranquility Partners LLC increased its stake in shares of AstraZeneca by 3.3% in the second quarter. Tranquility Partners LLC now owns 5,735 shares of the company’s stock worth $344,000 after buying an additional 185 shares during the period. Coastline Trust Co increased its position in AstraZeneca by 2.5% during the 1st quarter. Coastline Trust Co now owns 9,884 shares of the company’s stock valued at $491,000 after purchasing an additional 245 shares during the period. Lincoln National Corp increased its position in AstraZeneca by 2.2% during the 1st quarter. Lincoln National Corp now owns 11,606 shares of the company’s stock valued at $577,000 after purchasing an additional 249 shares during the period. Thomas White International Ltd. boosted its holdings in shares of AstraZeneca by 0.8% during the 1st quarter. Thomas White International Ltd. now owns 34,367 shares of the company’s stock valued at $1,709,000 after buying an additional 273 shares in the last quarter. Finally, Westover Capital Advisors LLC boosted its holdings in shares of AstraZeneca by 6.0% during the 1st quarter. Westover Capital Advisors LLC now owns 4,885 shares of the company’s stock valued at $243,000 after buying an additional 275 shares in the last quarter. Institutional investors own 13.88% of the company’s stock.

Shares of AstraZeneca stock opened at $58.50 on Tuesday. The stock has a market cap of $181.25 billion, a price-to-earnings ratio of 40.63, a PEG ratio of 1.21 and a beta of 0.53. The firm’s 50-day moving average is $57.80 and its 200 day moving average is $55.45. AstraZeneca PLC has a 1 year low of $46.48 and a 1 year high of $60.93. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.23 and a quick ratio of 1.01.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Wednesday, July 28th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.02. The company had revenue of $8.22 billion for the quarter, compared to analysts’ expectations of $7.79 billion. AstraZeneca had a net margin of 12.77% and a return on equity of 40.02%. On average, equities analysts expect that AstraZeneca PLC will post 2.64 EPS for the current fiscal year.

The business also recently announced a semi-annual dividend, which was paid on Monday, September 13th. Shareholders of record on Friday, August 13th were paid a dividend of $0.45 per share. This represents a yield of 2.4%. The ex-dividend date of this dividend was Thursday, August 12th. AstraZeneca’s dividend payout ratio is currently 68.16%.

AZN has been the topic of a number of research reports. SVB Leerink boosted their target price on shares of AstraZeneca from $69.00 to $71.00 and gave the company an “outperform” rating in a report on Monday. JPMorgan Chase & Co. initiated coverage on shares of AstraZeneca in a report on Thursday, August 12th. They set an “overweight” rating on the stock. UBS Group restated a “buy” rating on shares of AstraZeneca in a report on Thursday, June 17th. Citigroup restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, July 21st. Finally, Morgan Stanley reiterated an “overweight” rating on shares of AstraZeneca in a research note on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and a consensus target price of $123.00.

AstraZeneca Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Read More: What is a Reverse Stock Split?

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.